Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$0.26
-$0.14(-35.52%)
At close: 4:00 PM EDT
$0.26
-$0.14(-35.52%)
Day’s Range― - ―
52-Week Range$0.23 - $4.31
Previous CloseN/A
Volume5.72M
Average Volume (3M)309.34K
Market Cap
$905.98K
Enterprise Value$12.56M
Total Cash (Recent Filing)$441.00K
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding3,609,471
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap13.87
Enterprise Value/Revenue11.34
Enterprise Value/Gross Profit12.39
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendRapid TTM revenue growth (~501%) signals meaningful early commercial traction for the VIVO system and improving market adoption. Over the next 2–6 months sustained top-line momentum can translate into higher recurring procedure-related revenue and stronger site economics if the company converts pilot sites to repeat users.
Proprietary Non-invasive VIVO SystemA differentiated, non-invasive 3D mapping technology provides structural competitive advantage in cardiac electrophysiology by addressing pre-procedure planning needs. Durable clinical utility supports recurring per-procedure and service revenue streams and aids commercial differentiation versus invasive-only alternatives.
Recent Structured Financings Improved LiquidityThe $2.821M Series C-4 private placement and related financings, plus a $1M strategic placement, materially bolster near-term liquidity and reshape capital structure. This extends runway and reduces immediate solvency pressure, enabling continued commercialization and operational execution in the medium term.
Bears Say
Tiny Revenue BaseA very small absolute revenue base constrains the firm's ability to absorb fixed R&D, sales and G&A costs, making margin improvement and operating leverage difficult. Without material scale-up, high fixed-cost volatility will persist and slow progress toward self-sustaining operations over the next several quarters.
Persistent Cash BurnSustained negative operating and free cash flow indicates the business consumes capital faster than it generates it, forcing dependence on external financings. This structural cash-burn elevates financing and dilution risk and limits ability to invest in commercialization or product development without additional capital.
Extremely Negative Profitability MetricsVery large negative margins and deeply negative ROE reflect a cost structure far exceeding current revenue. Such structural unprofitability implies the company must either materially scale revenue, cut costs, or reprice services to approach sustainable margins; otherwise profitability remains a distant prospect.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.23 and its highest was $4.31 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $905.98K.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 13 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 3,609,471 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc., headquartered in Fort Mill, South Carolina, is dedicated to creating and distributing electrophysiology products. Their mission is to enhance treatment and outcomes for U.S. patients suffering from cardiac arrhythmias by providing innovative technologies and solutions to patients, hospitals, and physicians. Their premier product, the View into Ventricular Onset System (VIVO), is a non-invasive 3D cardiac mapping solution designed to accurately locate the origin points of idiopathic ventricular arrhythmias in patients with otherwise healthy hearts, before they undergo electrophysiology procedures. Additionally, they offer LockeT, a device for suture retention, and the Amigo Remote Catheter System, a robotic arm used for precise catheter control. The company, previously known as Ra Medical Systems, Inc., officially adopted the name Catheter Precision, Inc. in August 2023.
Technical Analysis
Ownership Overview
0.39%
Insiders
0.23% Mutual Funds
<0.01% Other Institutional Investors
99.38% Public Companies and
Individual Investors